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ABSTRACT
Background: During the period of this study, the American Academy of
Pediatrics (AAP) 2006 guidelines recommended respiratory syncytial virus
(RSV) prophylaxis for infants 32 to 35 weeks gestation age (wGA) with
two or more of ﬁve risk factors (RFs). New recommendations have
recently been published in 2009. The cost implications of expanding this
list of RFs to include other evidence-based RFs like passive smoke expo-
sure (PSE), crowded living conditions (CLCs), and young chronological
age (YCA) are unclear.
Methods: We estimated the prevalence of RSV RFs in a US sample of
infants 32 to 35 wGA referred for prophylaxis from nine specialty phar-
macy providers during the 2007–2008 season. We estimated the percent
eligible for RSV prophylaxis under various potential RF coverage policies.
Using a budget impact model, we calculated the per-member-per-month
(PMPM) cost for each policy in 2007 USD for a hypothetical one million
member plan.
Results: Infants 32 to 35 wGA represented 0.08% of the plan. Approxi-
mately 20.2% of these infants met at least two or more of ﬁve AAP RFs.
Expanding this list to include one additional RF of PSE, CLC, or YCA
increased the percent of infants potentially prophylaxed to 29.9%, 23.9%,
and 47%, respectively. Adding all three RFs to the list (two or more of
eight) increased the percent of infants potentially prophylaxed to 55.6%,
and increased payer costs by 9 cents PMPM.
Conclusion: Expanding the AAP RF criteria to include PSE, CLC, and
YCA would identify more 32 to 35 wGA infants at high risk for severe
RSV disease at an acceptable budget impact.
Keywords: budget impact, palivizumab, premature infants, respiratory
syncytial virus, risk factors.
Introduction
Respiratory syncytial virus (RSV) is the most common cause of
bronchiolitis and pneumonia among infants and young children
[1]. Infants born prematurely (gestational age 35 weeks), and
those with chronic lung disease (CLD) or hemodynamically sig-
niﬁcant congenital heart disease (CHD) are at high risk for
developing severe RSV disease [2,3]. Palivizumab is the ﬁrst
monoclonal antibody licensed for use in pediatric infectious dis-
eases and currently is the only approved drug for RSV immuno-
prophylaxis [2,4].
During the period of this study, the American Academy of
Pediatrics (AAP) 2006 guidelines recommended prophylaxis for
premature infants 32 to 35 weeks gestation age (wGA) who have
two or more of the following ﬁve risk factors (RFs): school-age
sibling, day care attendance, exposure to environmental air pol-
lutants (except passive smoke exposure [PSE]), underlying neu-
romuscular disorder, or congenital abnormality of the airways
[3]. New recommendations have recently been published in
2009. Additional factors have also been shown to increase risk
for RSV hospitalization in preterm infants. These include expo-
sure to cigarette smoke, young chronological age (YCA) (birth
less than or equal to 3 months before or birth during the RSV
season), low birth weight (<2500 g), crowded living conditions
(CLCs) (greater than or equal to four living in the home), family
history of asthma, and multiple births [5–21].
Recently, it has been reported that PSE, CLCs, and YCA,
when added to the existing AAP RFs, identiﬁed additional infants
32 to 35 wGA at high risk for RSV hospitalization (odds ratio
[OR] = 2.41; 95% conﬁdence interval: 1.46–3.99) [22]. Among
infants 32 to 35 wGA with these multiple RFs, the RSV hospi-
talization rate was between 7% and 8%, which is similar to rates
seen among infants <32 wGA (hospitalization rate of 6.5% in
unprophylaxed group [2]) for whom prophylaxis is routinely
recommended without RF requirement. These data suggest that a
greater proportion of RSV hospitalizations could be prevented if
these additional RFs were included when selecting candidates for
prophylaxis. Numerous studies have found strong evidence sup-
porting PSE, CLCs, and YCA as signiﬁcant RFs for RSV disease
[5,7,9,13,15,17,18,21,23–27]. Recently, a risk-scoring predictive
tool for Canadian infants born at 33–35 wGA showed that
CLCs, smoking, and birth during RSV season (a varied deﬁnition
of YCA) all contributed signiﬁcantly to the risk for RSV hospi-
talization. This model was validated using data from a nested
case control study in infants 33–35 wGA from Spain [28].
The AAP has considered both public health concern and the
economic burden to the health-care system in making their rec-
ommendations [3]. Broadening the list of current RF-based
guidelines for RSV immunoprophylaxis could be costly to health
plans. It is unclear how many additional infants would be eligible
to receive prophylaxis if more RFs were added to the current
AAP recommendations. Therefore, the aim of this study was
to estimate the budget impact of expanding the AAP RSV
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prophylaxis recommendations on a hypothetical million-member
health plan, based on the prevalence of RSV RFs among infants
32 to 35 wGA found in a nationwide sample in the United States.
Methods
We conducted a cross-sectional study of infants 32 to 35 wGA
referred for prophylaxis between July 1, 2007 and January 31,
2008 (represents 80–90% of referred cases in a season) from a
Specialty Distribution Network (SDN) in the United States to
examine the prevalence of RSV RFs. To understand variability in
RF prevalence from a nonreferred population, we also examined
a retrospective national medical record review from pediatric
clinical practices during the 2006–2007 RSV season. The RF
prevalence data from the SDN database were then used in an
economic analysis to understand the budget impact of various
coverage policies for infants 32 to 35 wGA.
SDN
The SDN includes regional and national specialty pharmacy
providers that distribute palivizumab to physician ofﬁces in the
United States. Specialty pharmacy services commonly distribute
and manage injectables, infusions, and therapies that are high in
cost or require complex care. Physicians submit palivizumab
referrals to the specialty pharmacy provider. Usually, the spe-
cialty pharmacy veriﬁes the patient’s beneﬁts with their insurance
provider, and if eligible, ships the product to the patients’ physi-
cian for administration. Information collected on physician refer-
ral forms typically includes birth year, gestational age, underlying
comorbidities (CLD and CHD), and presence of RSV RFs. As
this is a one-time data submission, patients are not tracked
uniformly over time, so outcome information is not available.
RFs routinely collected include day care attendance, school-age
siblings, neuromuscular disease, congenital airway disease, expo-
sure to environmental pollution, multiple births, CLCs, low birth
weight, and family history of asthma. The deﬁnition of each RF
is not standardized and is at the discretion of the referring phy-
sician. The form also documents requesting physician and
patient’s insurance information.
Analysis of SDN data. We included data from the nine largest
national distributors from this network (as these provide service
for a majority of the patients [70%] who receive palivizumab in
physician ofﬁces and offer consistent, complete, and timely data)
to understand the prevalence of RSV RFs (AAP and others) in
infants 32 to 35 wGA. Infants 32 to 35 wGA referred for pro-
phylaxis from July 1, 2007 to January 31, 2008 were included.
The sample included infants with private or Medicaid insurance.
We excluded those infants who had missing data on RF infor-
mation, and patients with CLD and/or CHD.
Our analysis focused on the ﬁve AAP RFs and those addi-
tional RFs with the strongest level of evidence: PSE [24–26],
CLCs [5,7,9,15], and YCA [9,13]. The SDN database has only
one ﬁeld for environmental pollution and passive smoking expo-
sure. To isolate the impact of each of these RFs, we randomly
tagged each occurrence of the original environmental pollution
variable as either PSE or environmental pollution exposure (not
because of smoking) based on the assumption that overall
smoking rates in this population would mimic a national
smoking prevalence rate of 20.1% [29]. Thus, prevalence of
environmental pollution was 28.4% from the SDN database.
This was tagged as PSE for 20.1%, and environmental pollution
exposure not because of smoking for 8.3%. Because of the
Health Insurance Portability and Accountability Act regulations,
personal health information such as birth date was not captured
in the SDN database. Therefore, we randomly imputed YCA
based on the distribution of births between August 1, 2005 and
March 31, 2006 in a national chart review study [22].
Analysis of medical records review. Because the SDN is a
referral-based distribution network, we used another data source
to cross validate our prevalence estimates of RFs. A retrospective
chart review study was conducted using medical records in pedi-
atric clinical practices in 43 states. These states were chosen for
geographic and seasonal diversity. Pediatricians were approached
if they had between 3 and 30 years of experience in clinical
practice, managed at least one premature infant, and prescribed
palivizumab. Pediatricians who met the inclusion criteria were
selected by quota sampling across six geographic regions.
Medical records on every infant born at 35 wGA or less between
March 31, 2006 and April 30, 2007 were collected through an
Internet-based questionnaire. Participating physician ofﬁces
extracted information from medical records onto a standardized
questionnaire for up to ﬁve patients, and were responsible for the
completeness and accuracy of the questionnaire. Patients were
selected as per participating physician’s discretion, and included
patients with both Medicaid and private insurance. Data were
collected on birth date, demographic information, patient’s
insurance information, documented RFs, and palivizumab
request status.
Budget Impact Model Overview
A budget impact model was developed to approximate the
impact of providing immunoprophylaxis for prevention of RSV
to high-risk infants in a hypothetical health plan with one million
enrollees. Because this study is from a payer perspective, we did
not include indirect costs in this analysis. We incorporated costs
associated with RSV immunoprophylaxis and the direct medical
costs associated with RSV hospitalizations. The cost of prophy-
laxis is based on the number of doses of palivizumab adminis-
tered. The model determines the number of doses an infant
receives based on the month of birth, and predicts the corre-
sponding chronological and gestational age adjusted weight at
each monthly administration of prophylactic drug [30,31].
Palivizumab costs were calculated using the least expensive com-
bination of 50 mg and 100 mg vials of palivizumab based on
average Medicaid and private insurance adjusted costs. Prob-
abilities and resource use parameters for RSV immunoprophy-
laxis and RSV hospitalization were primarily based on data
collected from: 1) the IMpact study (International Multi-center
Phase III Clinical Trial in RSV) [2]; and 2) the cardiac study [32].
Because these clinical trials did not show a difference in adverse
events between treatment groups and placebo, we did not incor-
porate adverse event costs into the analysis. The model assumes
all infants hospitalized for RSV receive follow-up care consisting
of one level 4 outpatient visit with a pediatrician (CPT-99214).
Approximately half of the hospitalizations are assumed to have
come through the emergency department [33]. Table 1 lists
details of the key input variables that were used in the model
calculation.
The US national birth rate (1.4%) was applied to the plan
population (1 million) to estimate the size of the birth cohort
[34]. The national birth rate represents a combination of
approximately 75% private insurance and 25% Medicaid popu-
lations based on birth rates alone [35,36]. From this information,
the distribution of different gestational age cohorts was estimated
after accounting for neonatal mortality [34]. The prevalence of
CLD and CHD, and their overlap with gestational age was
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adapted from a national randomized chart review of 2,199
infants conducted during 2005–2006 RSV season (July 2005 to
June 2006) [37]. We also calculated baseline immunoprophylaxis
rates in the high-risk infant groups of <32 wGA, CLD, and CHD
from this study (Table 1) [37]. For preterm-only infants, the
evaluation period was for their ﬁrst RSV season; for CLD, CHD
infants, we assumed 50% of those eligible in the previous year
were prophylaxed in their second season. The model estimated
the overall and incremental costs for the hypothetical health
plan. Costs were reported as both totals and on a per-member-
per-month (PMPM) basis. The primary analysis followed AAP
recommendations to provide immunoprophylaxis, while subse-
quent analyses examined the impact of expansion of RFs. The
incremental PMPM was then compared to existing PMPM values
of other drug classes as provided by a pharmacy beneﬁt manage-
ment organization [38]. We also used the annual PMPM costs for
child health insurance from the AAP Pediatric Medical Cost
model to understand how expansion of RFs would affect overall
child health insurance costs [39].
Model assumptions. The base case assumes that the RSV season
lasted for 5 months from November to March [3], giving an
average of 3.75 doses for a mix of in-season and out-of-season
infants, assuming equal likelihood of birth over 12 months.
We made several assumptions, some of these bias the model
toward increased palivizumab costs. We assume: 1) any unused
portions of vials arewasted; 2) prophylaxis occurs in the physician
ofﬁce setting and therefore incurs costs for physician visit (CPT-
99391) and for administration of prophylaxis (CPT-90772); 3)
there is 100% adherence to the recommended number of doses; 4)
costs are based on wholesale acquisition of palivizumab (adjusted
for payer mix); 5) no cost offsets because of reduction in outpa-
tient RSV lower respiratory tract infections [2]; 6) no reduction in
hospital length of stay among prophylaxed infants with break-
through RSV hospitalizations (i.e., disease severity reduction) [2];
7) no costs because of prior authorization to the health plan; 8) no
change in RSV mortality [2] or reductions in recurrent wheezing
episodes later in childhood; and 9) the nine selected distributors
were assumed to be representative of palivizumab patients.
Costs. Costs were categorized as palivizumab prophylaxis costs
and RSV disease-related direct costs. Palivizumab prophylaxis
costs included direct medical costs (i.e., prophylaxis acquisition
and administration costs). RSV disease-related direct costs
included costs for hospitalization and post-hospital follow-up
care. Costs were adjusted to 2007 USD, when necessary, using
the medical care services component of the consumer price index
[40].
An analysis of MedStat MarketScan data, a national, self-
insured employer database involving 18 million covered lives,
was used to determine the cost of RSV hospitalization for pre-
mature infants with CLD, with CHD, and without CLD and
CHD [41]. Infants with a Diagnosis Related Groups (DRG) code
for premature birth (385–388) and an International Classiﬁca-
tion of Diseases, 9th Revision (ICD-9) code for GA (765.21–
765.28) identiﬁed between May 1 and April 30 over three
seasons (2004–2006) were followed for hospitalizations because
of RSV bronchiolitis and pneumonia (ICD-9 codes 079.6,
466.19, and 480.1). CLD and CHD patients were identiﬁed
using speciﬁc ICD-9 codes (CLD: 770.7; CHD: 425.5, 745.0–6,
746.0–3, 746.7, 747.0–1, 747.4). For CHD infants, the diagnosis
codes had to appear at least twice to conﬁrm the presence of
CHD (presence of a single code could indicate a diagnostic test
and not a conﬁrmed case). An average RSV hospitalization cost
was calculated from the allowed payment for each group. We
assumed that each infant discharged after their RSV hospitaliza-
tion had at least one outpatient follow-up visit. All other costs
were obtained from published literature or standard costing
sources [42–44].
Budget impact analysis. The model estimated budget impact for
expansion of the list of RFs to include PSE, CLCs, and YCA
individually or in different combinations. The analysis evaluated
budget impact on a 1-year time frame, so discounting was not
applied. Sensitivity analyses were conducted to ascertain which
variables were most inﬂuential in the model.
Results
SDN
The database had a total of 29,124 infants 32 to 35 wGA, of
which 17,522 infants satisﬁed the study inclusion and exclusion
criteria. The geographic distribution was Northeast (27.8%),
Southwest (23.5%), Southeast (21.0%), Central (14.6%), and
Western (13.2%) United States (Table 2). Approximately 22.8%
of subjects were 32 wGA, 24.3% were 33 wGA, 30.5% were
34 wGA, and 22.5% were 35 wGA.
Table 1 Clinical and unit cost model inputs
Risk group prevalence Percentage (%)
CLD in <32 wGA 16.08 [37]
CLD in 32–35 wGA 4.94 [37]
CHD in <32 wGA 4.10 [37]
CHD in 32–35 wGA 1.26 [37]
CHD in >35 wGA 0.71 [37]
Immunoprophylaxis rates for high-risk groups (except 32–35 wGA).
CLD 90 [37]
CHD 35 [37]
<32 wGA 85 [37]
Clinical parameters Palivizumab (%) No prophylaxis (%)
CLD: percent having at least one
RSV hospitalization
7.9 12.8 [2]
CHD: percent having at least one
RSV hospitalization
5.3 9.7 [32]
<32 wGA: percent having at least one
RSV hospitalization
1.85 6.5 [2]
32–35 wGA: percent having at least
one RSV hospitalization
1.8 10 [2]
Unit cost parameters Cost (2007 USD)
Prophylaxis-related direct costs
Palivizumab, 50 mg vial $712.2 [42]
Palivizumab, 100 mg vial $1,344.8 [42]
Outpatient pediatric visit for prophylaxis (CPT 99391) $133 [43]
Palivizumab administration (CPT 90772) $31 [43]
RSV-related direct costs
CLD: RSV hospitalization* $48,278 [41]
CHD: RSV hospitalization* $21,932 [41]
Premature infants: RSV hospitalization* $17,542 [41]
ER visit $506 [44]
Post-hospital outpatient pediatric visit (CPT 99214) $128 [43]
*Results based on a study of privately insured infants born May 2004 to April 2006.Average
RSV hospitalization payment was obtained from admissions with an RSV-speciﬁc diagnostic
code (ICD-9 CM 466.11, 480.1, or 079.6) among premature infants without CLD, with CLD
(770.7), and with CHD (425.5, 745.0–6, 746.0–3, 746.7, 747.0–1747.4).
CHD, congenital heart disease; CLD, chronic lung disease; RSV, respiratory syncytial virus;
wGA, weeks gestation age; ICD-9 CM, International Classiﬁcation of Diseases, 9th Revision,
Clinical Modiﬁcation.
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Prevalence of single RFs. Approximately 39.5% of infants had a
school-age sibling, 30.5% attended day care, 0.7% had neuro-
muscular disease, 2.1% had congenital abnormalities of the
airways, and 8.3% had exposure to environmental pollution (no
PSE). The prevalence rates of non-AAP RFs were as follows:
20.1% PSE, 51.4% low birth weight, 8.0% CLCs, 26.0% mul-
tiple births, 68.6% YCA (born August 1 to March 31 of the
seasonal year), and 9.6% family history of asthma.
Prevalence of multiple RFs. The percentage of infants in the 32
to 35 wGA group that would be eligible for RSV immunopro-
phylaxis according to AAP recommendations (two or more of
ﬁve) was 20.2%. Adding PSE to the AAP RFs increased the
percentage of infants eligible to 29.9%, while the addition of
CLCs or YCA increased the percentage to 23.9% and 47.0%,
respectively. When a combination of two additional RFs was
added to the AAP recommendations (two or more of seven), the
following percentage of infants would be eligible for palivi-
zumab: 1) PSE and CLC is 32.7%; 2) PSE and YCA is 54.3%;
and 3) CLCs and YCA is 49.0%. Finally, when all three RFs are
added to AAP recommendations (two or more of eight), 55.6%
of 32 to 35 wGA infants would be candidates for RSV immuno-
prophylaxis (see Table 3).
Cross-Validation Data Results from
Medical Records Review
Data on a total of 905 patients 35 wGA were available in this
study. Of these, 539 were in the 32 to 35 wGA cohort and used
for RF estimates. The available demographic data from these
patients are presented in Table 2. The regional distribution was
within 5% for all regions as compared to the SDN data, except
for the central region. The GA distribution had similar trends as
the SDN data, and the data were almost equally represented by
each gender.
There was some variation in the prevalence of individual or
single RFs between the two databases (SDN and medical records
review). The prevalence of neuromuscular disease, congenital
airway abnormalities, and environmental exposure not because
of smoking was similar across both data sources (Table 3). There
was more variation in the proportion of infants with day care or
smoking exposure and presence of low birth weight. Never-
theless, when combination of RFs was assessed, this variation
decreased. From the current AAP recommendation (two or more
of ﬁve) to the full expanded list (two or more of eight) resulted in
an increase from 15.2% to 52.9% of 32 to 35 wGA infants being
eligible for prophylaxis in the medical record analysis compared
to the SDN data incremental estimate from 20.2% meeting AAP
to 55.6% meeting AAP with smoking, overcrowding, and YCA.
Budget Impact of Additional RFs
Infants 32 to 35 wGA are 5.6% of all US births; however, they
comprise <0.08% of all insured lives or approximately 810 (754,
with exclusion of CLD and CHD) infants per 1,000,000 health
plan members as per our calculation (Fig. 1) [34,37,45–47].
Table 4 summarizes the effect of expanding the RFs for RSV
prophylaxis, and its impact on costs. Adding PSE as the sixth RF
resulted in an incremental increase of 3 cents PMPM (total
Table 2 Patient demographics
Characteristics
Specialty Distribution
Network frequency n (%)
Medical Records
Review frequency n (%)
N = 17,552 N = 539
Region
Northeast 4,870 (27.8) 127 (23.6)
Central 2,560 (14.6) 135 (25.0)
Southwest 4,122 (23.5) 116 (21.5)
Southeast 3,690 (21.0) 87 (16.1)
West 2,310 (13.2) 74 (13.7)
Gestational age (weeks)
32 3,995 (22.8) 99 (18.4)
33 4,263 (24.3) 115 (21.3)
34 5,349 (30.5) 181 (33.6)
35 3,945 (22.5) 144 (26.7)
Gender (male) — 278 (51.6)
Table 3 Prevalence of risk factors in Specialty Distribution Network and National Medical Record Review Study
Risk factors
Specialty Distribution Network National Medical Record Review
Numerator n
(N = 17,552)
Percentage
(%)
Numerator n
(N = 539)
Percentage
(%)
School-attending sibling 6,928 39.5 178 33.0
Day care attendance 5,353 30.5 80 14.8
Neuromuscular disease 122 0.7 6 1.1
Congenital airway abnormality 376 2.1 13 2.4
Environmental pollution 1,450 8.3 65 12.1
Passive smoke exposure (PSE) 3,526 20.1 66 12.2
Low birth weight 9,023 51.4 422 78.3
Crowded living conditions (CLCs) 1,406 8.0 160 29.7
Multiple births 4,562 26.0 197 36.5
Young chronological age (YCA) 12,039 68.6 399 74.0
Family history of asthma 1,681 9.6 120 22.3
American Academy of Pediatrics (AAP) (any two of ﬁve: day care
attendance, school-age sibling, neuromuscular disease, congenital
airway abnormality, environmental pollution)
3,542 20.2 82 15.2
AAP + PSE (any two out of six) 5,240 29.9 98 18.2
AAP + CLCs (any two out of six) 4,197 23.9 147 27.3
AAP + YCA (any two out of six) 8,252 47.0 211 39.1
AAP + PSE + CLCs (any two out of seven) 5,740 32.7 160 29.7
AAP + PSE + YCA (any two out of seven) 9,534 54.3 234 43.4
AAP + CLCs + YCA (any two out of seven) 8,594 49.0 268 49.7
AAP + CLCs + PSE + YCA (any two out of eight) 9,782 55.6 285 52.9
Note: The Specialty Distribution Network data do not report birth date.A random imputation was done to estimate YCA.Also, Specialty Distribution Network bundles the environmental
pollutants and PSE variables as one; this variable was split using random imputation based on smoking rates from CDC data [29].
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incremental costs of $305,490). Adding CLCs to the AAP RFs
increased costs by 1 cent PMPM (total incremental costs of
$118,037). The addition of YCA increased incremental PMPM
by 7 cents (incremental total costs of $854,974) to the health
plan.
If the hypothetical health plan expanded its policy to include
two additional RFs, so infants with two or more of seven RFs
receive prophylaxis, three budget impact scenarios emerged.
First, the addition of PSE and CLCs resulted in an incremental
PMPM of 3 cents (total incremental cost of $398,775). Adding
PSE and YCA resulted in an incremental PMPM cost of 9 cents
(total incremental costs of $1.09 million). Adding CLCs and
YCA resulted in an incremental PMPM of 8 cents (total incre-
mental cost of $918,778). Finally, inclusion of all three addi-
tional RFs to the AAP recommendations (two or more of eight
receive prophylaxis) resulted in a PMPM increase of 9 cents
(total incremental cost of $1.13 million). In all of the scenarios,
there was a <0.1% increase in child health insurance costs. Total
child health insurance costs were obtained from 2006 AAP
PMPM calculator, and estimated to be $116.93 PMPM in 2008
dollars after consumer price index adjustments [39,40]. Compar-
ing the PMPMs of RSV prophylaxis with those for other biologic
therapies demonstrates that cost of an expanded RSV prophy-
laxis policy was within the low range of commonly reimbursed
specialty pharmaceutical products (Fig. 2). Budget estimates
using the prevalence data from the smaller sampled medical
record review study did not appreciably change the results (data
not shown).
The most inﬂuential variables affecting the budget calcula-
tions were the costs of palivizumab, RSV hospitalization costs,
increase in season length, and birth rate (Table 5 and Fig. 3). In
various policy scenarios, expansion of the RFs with variation of
these inﬂuential variables increased the budget by less than 10
cents PMPM.
Discussion
Palivizumab is indicated to prevent severe RSV disease for high-
risk pediatric populations including infants 35 wGA [4]. AAP
RFs, largely identiﬁed in the 2006 Red Book guidelines, were
recommended for infants 32 to 35 wGA to help manage costs.
Speciﬁcally, the guidelines state, “Although palivizumab has been
shown to decrease the likelihood of hospitalization in infants
born between 32 and 35 weeks of gestation . . . the cost of
administering prophylaxis to this large group of infants must be
considered carefully [3].” Cost-effectiveness analysis in this
population is challenging, as there is no consensus on what the
utility beneﬁts would be in infants. Most published cost-
effectiveness for palivizumab has used proxy data from parents,
which can be criticized as not representative of society’s
Figure 1 Estimating the number of infants 32 to 35 weeks gestation age in a million-member plan. CHD, congenital heart disease; CLD, chronic lung disease.
Table 4 Number of incremental infants 32–35 weeks gestation age (wGA) prophylaxed and cost implications
Recommended risk factors (2 of N)
Number and percent of infants 32–35 wGA
eligible for prophylaxis in plan*
N = 754
Incremental increase
in PMPM costs, $
Incremental increase
in total costs, $
American Academy of Pediatrics (AAP)‡ 152 (20.2) Reference Reference
AAP + passive smoke exposure (PSE) 226 (29.9) +0.03 +309,450
AAP + crowded living conditions (CLCs) 180 (23.9) +0.01 +118,037
AAP + young chronological age (YCA) 355 (47.0) +0.07 +854,974
AAP + PSE + CLCs 247 (32.7) +0.03 +398,775
AAP + PSE + YCA 410 (54.3) +0.09 +1,087,859
AAP + CLCs + YCA 370 (49.0) +0.08 +918,778
AAP + CLCs + PSE + YCA 419 (55.6) +0.09 +1,129,332
*Plan size is 1 million members; prevalence is based on Specialty Distribution Network database.
‡AAP: presence of any two of ﬁve risk factors: day care attendance, school-age sibling, neuromuscular disease, congenital airway abnormality, and environmental pollution.
Note: Using the estimate from the medical record review data gave an incremental PMPM of 10 cents for the inclusion of all three additional risk factors to the AAP recommendations (two
or more of eight receive prophylaxis).
PMPM, Per-member-per-month.
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preference [48–53]. One study found that RSV illness in infants
had an impact on the quality of life of parents (caregivers) [54].
This was not included in the aforementioned cost-effectiveness
analysis, and therefore a full assessment of beneﬁts when illness
is avoided is not captured. Early cost-effectiveness studies on
palivizumab have been criticized for not presenting data in cost–
utility terms or had methodological shortcomings such as not
factoring in weight of infants over time [55]. Recently, six cost-
effectiveness analyses of palivizumab followed the accepted stan-
dards of cost-effectiveness estimation [48–53]. Of these, four
were conducted in the EU, one in Canada, and one in the United
States. Five found RSV prophylaxis with palivizumab to be cost-
effective, while Elhassan et al. reported that prophylaxis was not
cost-effective even for infants <32 wGA for whom prophylaxis
was routinely recommended [50]. Nevertheless, Elhassan et al.
did not consider consequences following RSV outside of hospi-
talization in their model [50,56]. Elhassan et al. acknowledged
that demonstration of a reduction in wheezing-related long-term
consequences could make prophylaxis more economically attrac-
tive [50]. Recent data suggest that recurrent wheezing is associ-
ated with early infancy RSV and that prophylaxis could decrease
risk of recurrent wheezing [57–61]. Most recently, Lanctot et al.
found prophylaxis to be cost-effective for infants 32 to 35 wGA
with RSV RFs, but not in those without RFs [51].
Unlike these cost-effectiveness analyses, which attempt to
measure whether prophylaxis is “worth” spending money on,
our analysis is the ﬁrst, to our knowledge, to estimate the
budget impact of prophylaxis and thus the “affordability” to
payers. Contrary to the popular belief that infants 32 to
35 wGA are too large of a group to receive prophylaxis [3], we
found that infants 32 to 35 wGA are not a “large group” when
compared to total insured lives. In a million-member health
Figure 2 Per-member-per-month (PMPM) costs of leading specialty biologics compared to respiratory syncytial virus (RSV) prophylaxis with palivizumab [38].
*RSV prophylaxis (palivizumab) is 17th in ranking of all specialty biologics by PMPM cost. †RSV prophylaxis expanded indicates a policy including smoking,
overcrowding and young chronological age as RSV risk factors (RFs) in addition to the 5 American Academy of Pediatrics RFs (extra 9 cents PMPM) based on our
calculation from Express Scripts data and is the only estimated information on the ﬁgure.All other values are total PMPMs for the particular therapy areas.
Table 5 Sensitivity analysis of the most inﬂuential variables*
AAP† + passive smoke
exposure (PSE)
AAP + crowded living
conditions (CLCs)
AAP + young
chronological age (YCA) AAP + PSE + CLCs + YCA
Scenario Two or more of six Two or more of six Two or more of six Two or more of eight
Base case (reference from Table 4) Reference Reference Reference Reference
Increase palivizumab costs by 10% +0.03 +0.02 +0.03 +0.03
Decrease palivizumab costs by 10% -0.03 -0.02 -0.03 -0.03
Increase RSV hospitalization costs by 25% -0.02 -0.01 -0.02 -0.02
Decrease RSV hospitalization costs by 25% +0.02 +0.02 +0.02 +0.02
Increase season length from 5 to 6 months +0.08 +0.08 +0.10 +0.11
Increase birth rate to 20/1000 from 14/1000 +0.09 +0.09 +0.11 +0.12
Decrease birth rate to 10/1000 from 14/1000 -0.06 -0.06 -0.07 -0.08
*Estimates are using the Specialty Distribution Network database.
†AAP: presence of any two of ﬁve risk factors: day care attendance, school-age sibling, neuromuscular disease, congenital airway abnormality, environmental pollution.
AAP, American Academy of Pediatrics; RSV, respiratory syncytial virus.
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plan, there are approximately 800 infants 32 to 35 wGA
(0.08%).
The addition of PSE, CLCs, and YCA to currently recom-
mended AAP RFs identiﬁed slightly more than half of these 800
infants in a million-member plan. The budget impact from
expanded prophylaxis coverage policies was low and well within
the range observed for other acceptable specialty pharmaceutical
therapies. Indeed, the overall change in child health insurance
costs from expanding RSV prophylaxis policies was small
(<0.1% estimated increase in PMPM costs). If we extrapolate the
increase in costs to a health plan to the US population, this would
mean an increase of $1.1 million times 300 or $330 million.
Typically, not all eligible patients receive prophylaxis, and there-
fore if we assume that 70% of the eligible would receive prophy-
laxis, the total cost increase is $231 million. In context to the
total health-care spend for the United States which exceeds $2.4
trillion in 2007, increasing RSV prophylaxis raises health-care
costs by 0.01% [62]. Comparatively, 10% to 12% of all health-
care spending occurs for end-of-life care [63]. Our ﬁndings
suggest greater expenditures earlier in life and are reasonable
(<0.01% of additional costs).
The evidence demonstrating PSE, CLCs, and YCA as RSV
hospitalization RFs has increased in recent years. Predictive mod-
eling reveals increased OR with each of these RFs. McConnochie
and Roghmann reported an OR of 3.21 for RSV hospitalizations
in the presence of any smoking in the household versus no
smoking in the household [6], whereas analysis of The Pediatric
Investigators Collaborative Network on Infections in Canada
(PICNIC) data revealed an OR of 1.87 for >2 smokers in the
household after adjusting for other RFs [7]. Similar analysis for
maternal smoking during pregnancy revealed an OR of 1.6
versus no maternal smoking during pregnancy [9]. With CLCs,
the OR varies based on deﬁnition used. For four or more indi-
viduals in the household including the patient, it was 1.91 [13];
for greater than ﬁve individuals in the household including the
patient, it was 1.69 [7]; and for two or more individuals in the
same bedroom, it was 4.7 [64]. The comparison group was
absence of CLCs by each deﬁnition used. OR for effect of YCA
versus absence of YCA on RSV hospitalization again varies with
deﬁnition used, but shows a consistent increased risk. For birth
during the months of November, December, and January, it was
4.88 [7]; if age at start of RSV season was10 weeks, it was 3.95
[13]; and if age <3 months at season start, it was 1.63 [5].
Recently, Makari et al. found that a policy including PSE,
CLCs, and YCA would identify a subset of infants 32 to 35 wGA
currently not receiving prophylaxis, but who are at high risk for
RSV hospitalization [22]. The addition of these three RFs to AAP
guidelines may have prevented almost half of observed RSV
hospitalizations in that study. RFs predictive in a Spanish study
conducted by Figueras-Aloy et al. were comparable to those iden-
tiﬁed here, and included YCA at season onset, school-age siblings,
crowding, breast-feeding less than 2 months, and a family history
of wheezing [17]. In a Canadian study, Sampalis et al. developed a
risk-scoring tool, which incorporated smoking, crowding, and
infants born within season [28]. Infants with a high-risk score
from this tool had a 5- to 11-fold higher odds of RSV hospitaliza-
tion compared to infants with a low-risk score. In addition, the
PICNIC group also noted higher rates of RSV hospitalization
among infants with two or more RSV RFs compared to infants
having single or no RF history [7]. The FLIP-2 group demon-
strated that the risk of RSV hospitalization in preterm infants
(32–35 wGA) was associated with absolute chronological age of
<10 weeks at the onset of RSV season start (OR = 2.99), presence
of school-age siblings or day care attendance (OR = 2.04), and
smoking during pregnancy (OR = 1.61) [13]. Our study suggests
that expanding RSV RFs to include those signiﬁcantly associated
with RSV infection such as PSE, CLCs, and YCA has low budget
impact to a hypothetical health plan.
Our approach could be compared to Wegner et al.’s cohort
study, whereby he compared 32 to 35 wGA infants who received
prophylaxis versus those who did not receive prophylaxis in
North Carolina Medicaid, and concluded that there was no
direct cost savings [65]. The study groups in Wegner et al.’s study
were signiﬁcantly different in the distribution of race, multiple
births, and gestational age, all of which would potentially have
an effect on outcomes. Being an observational study, it does have
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Figure 3 Effects of inﬂuential variable inputs on difference in incremental per-member-per-month (PMPM) two of eight versus two of ﬁve.
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the limitations of confounding by indication and has limited
generalizability. Our approach concludes that prophylaxis of
additional infants would have an economic impact on the health
plan budget, but when administered in an evidence-based
manner to those at higher risk, the budget impact would be
acceptable.
Our study has important limitations. First, the SDN database
comprises infants referred for prophylaxis. It does not contain
data on infants who are not referred. A bias introduced from this
sample may be overrepresentation of RFs leading to a potential
overestimate of the budget impact. Second, we had to impute RFs
for YCA, and isolate environmental air pollutants from passive
smoking exposure. These imputations could introduce bias in
our prevalence estimates. Nevertheless, using a medical record
review source, we found that the number of infants that would
qualify for the various policies was roughly similar and did not
substantially result in different budget estimates. Third, the deﬁ-
nitions for certain RFs, such as CLCs or attending day care, are
variable, and this interpretation was left to the referring physi-
cians’ judgment. Nonetheless, our study does provide a close to
real-world estimate. Simple comparison of the RF data with a
different data source (medical records review) revealed some
variation in RF prevalence. In the absence of good epidemiologi-
cal data on prevalence of RFs and standard use of deﬁnitions for
RFs in this infant group, this approach appears to be a practical
way for forecasting costs. Fourth, we assumed that the data from
nine distributors would be representative of patients receiving
prophylaxis. Fifth, the model does not factor in important cost
offsets outside of preventing RSV hospitalizations (see assump-
tions), and these would lead to potential overestimation of the
budget impact of adding these RSV RFs. Also, our estimate for
cost of RSV hospitalizations is higher than some of the earlier
reports by Joffe et al., Loﬂand et al., Katz et al., Howard et al.,
and Wegner et al. who reported it to be between $3,355 and
$10,613 [65–69]. If adjusted for inﬂation, all but Wegner exceeds
the 75% of our cost used in the sensitivity analyses. Moreover, it
is below that published by Marchetti et al. who reported that the
cost of RSV hospitalization varied from $10,236 to $166,375
with an average of $19,190 [70]. Also, Katz et al. who reported
an average cost of RSV hospitalization of $10,613 published that
if there was PICU use, then the average cost of RSV hospitaliza-
tion was $17,640, and if hospitalization involved PICU use and
ventilator use, then it was $28,770 [68]. Not all the previous
studies reporting costs limited the population to preterm infants,
and most of these were estimates from the 1990s. Horn and
Smout have reported longer length of stay, ICU, and ventilation
use among preterm (both early and late) compared to term
infants [71]. Thus, our average cost of $17,542 (2007 USD) from
a group of privately insured preterm infants from 2004 to 2006
is not inconsistent with prior data. Finally, data used in our
calculation from patients with private insurance (i.e., cost of RSV
hospitalization) and clinical trials (IMpact, cardiac study) may
have limited generalizability [2,32,41].
In conclusion, infants 32 to 35 wGA represent a small pro-
portion of infants when compared to total insured lives. Pro-
viding prophylaxis for infants 32 to 35 wGA who are at high
risk for severe RSV disease because of passive smoking expo-
sure, CLCs, or having YCA is of low budget impact in our
model and in line with coverage for other important health-care
items and services. An expanded RF policy would help protect
more high-risk infants while not adding signiﬁcant costs to
health plans.
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